Table 1.
Patient characteristics (N=40)
| ALL | MBM | SBM | P value | |
|---|---|---|---|---|
| N | N | |||
| Number | 40 | 13(32.5%) | 27(67.5%) | |
| Sex | ||||
| Male | 22 | 10(76.9%) | 12(44.4%) | 0.090 |
| Female | 18 | 3(23.1%) | 15(55.6%) | |
| Median Age (Years, Range) | 50(22-66) | 49(37-66) | 52(22-66) | 0.909 |
| PS | ||||
| 0-1 | 12(92.3%) | 25(92.6%) | 1.000 | |
| 2 | 1(7.7%) | 2(7.4%) | ||
| Smoking history | ||||
| Active and former smoker | 5(12.5%) | 1(7.7%) | 4(14.8%) | 0.653 |
| Never smoker | 35(87.5%) | 12(92.3%) | 23(85.2%) | |
| Pathology | ||||
| Adenocarcinoma | 37(92.5%) | 12(92.3%) | 25(92.6%) | 0.690 |
| Neuroendocrine carcinoma | 2(5.0%) | 1(7.7%) | 1(3.7%) | |
| Adenosquamous carcinoma | 1(2.5%) | 0 | 1(3.7%) | |
| Initial Neurological symptoms | ||||
| Yes | 15(37.5%) | 3(23.1%) | 12(44.4%) | 0.298 |
| No | 25(62.5%) | 10(76.9%) | 15(55.6%) | |
| Treatment before Brain metastasis | 13 | 0 | ||
| Platinum-based Chemotherapy | 13(100%) | / | ||
| Crizotinib | 3(23.1%) | / | ||
| Others | 3(23.1%) | / | ||
| ALK-rearranged | 40(100%) | 13 | 27 | |
| EGFR mutation status | ||||
| Wild-type | 39(97.5%) | 13(100%) | 26(96.3%) | |
| unknown | 1(2.5%) | 0 | 1(3.7%) | |
| MBR(Observation>6 Months) | 31 | 8 | 23 | |
| enlargement | 7 | 1(12.5%) | 6(26.1%) | |
| increase | 9 | 2(25.0%) | 7(30.4%) | |
| >3 | 8 | 1 | 6 | |
| ≤3 | 2 | 1 | 1 | |
| stable or decrease | 14 | 5(62.5%) | 9(39.1%) | |
| Treatment after Brain metastasis | ||||
| Crizotinib without Local treatment | 0 | 6(22.2%) | ||
| WBRT | 2(15.4%) | 3(11.1%) | ||
| γ knife | 2(15.4%) | 3(11.1%) | ||
| resection | 1(7.7%) | 0 |
N: Number of Patients; MBM: metachronous brain metastases; SBM: synchronous brain metastases; PS: Performance Status; MBR: modality of brain recurrence; WBRT: whole brain radiotherapy.